Hester Biosciences Limited has submitted a mandatory regulatory declaration confirming that its promoters and promoter group did not create any encumbrances on their shareholdings during the financial year ended March 31, 2026. The declaration was filed with both BSE and NSE on April 3, 2026, in compliance with SEBI regulations.

Regulatory Compliance Declaration

The company filed the declaration pursuant to Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation mandates that promoters and promoter groups must declare annually whether they have created any encumbrances on their shareholdings during the financial year.

Promoter Group Representative

Mr. Rajiv Gandhi submitted the declaration on behalf of the promoters and promoter group. In his communication to the stock exchanges, he confirmed that during the financial year ended March 31, 2026, no encumbrances were made on promoter holdings, either directly or indirectly.

The declaration also requested that this disclosure be presented to the company's Audit Committee for their review and comments, ensuring proper internal governance oversight.

Stock Exchange Communication

The company's Company Secretary and Compliance Officer, Vinod Mali, formally communicated the declaration to both major stock exchanges where Hester Biosciences shares are listed.

Corporate Governance Significance

This annual declaration forms part of the regulatory framework designed to ensure transparency in promoter shareholding patterns. The requirement helps investors and regulators monitor any changes in promoter commitment to their shareholdings through encumbrances such as pledging or hypothecation of shares.

The timely filing of this declaration demonstrates Hester Biosciences' commitment to regulatory compliance and corporate governance standards. Such disclosures are essential for maintaining investor confidence and ensuring transparency in promoter shareholding arrangements.

Hester Biosciences Limited has submitted multiple regulatory compliance disclosures to stock exchanges, reinforcing its commitment to transparency and adherence to SEBI regulations. The company filed reports with both BSE Limited and National Stock Exchange of India Limited regarding its corporate status and quarterly compliance requirements.

Large Corporate Classification Disclosure

The company formally notified stock exchanges on 3 April 2026 that it does not fall under the Large Corporate category as defined by SEBI regulations. This disclosure was made in compliance with SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated 26 November 2018, which pertains to fund raising through debt securities by Large Corporates.

Quarterly Securities Compliance Report

On 8 April 2026, Hester Biosciences submitted its confirmation certificate for securities dematerialised/rematerialised during the quarter ended 31 March 2026. This submission was made under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate was received from the company's Registrar and Share Transfer Agent, MUFG Link Intime India Private Limited.

Corporate Information and Leadership

Hester Biosciences Limited operates from its headquarters and registered office located in Village Meda-Adraj, Taluka Kadi, District Mehsana, Gujarat. The company also maintains an Ahmedabad office at Pushpak, Panchvati Circle. Both regulatory disclosures were signed by Company Secretary & Compliance Officer Vinod Mali and Chief Financial Officer Ashish Desai, demonstrating proper corporate governance protocols.

Regulatory Framework Significance

These compliance submissions highlight the company's adherence to SEBI's regulatory framework. The Large Corporate classification disclosure ensures transparency in debt market operations, while the quarterly securities report maintains proper oversight of dematerialisation processes. Companies falling under the Large Corporate category are subject to specific regulations regarding fund raising through debt securities, making Hester Biosciences' confirmation of its non-classification important for investors and regulatory authorities.